ATE390931T1 - Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen - Google Patents

Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen

Info

Publication number
ATE390931T1
ATE390931T1 AT02734556T AT02734556T ATE390931T1 AT E390931 T1 ATE390931 T1 AT E390931T1 AT 02734556 T AT02734556 T AT 02734556T AT 02734556 T AT02734556 T AT 02734556T AT E390931 T1 ATE390931 T1 AT E390931T1
Authority
AT
Austria
Prior art keywords
soluble ctla4
allogenic
protecting
transplant
island
Prior art date
Application number
AT02734556T
Other languages
English (en)
Inventor
Christian Larsen
Thomas Pearson
Andrew Adams
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE390931T1 publication Critical patent/ATE390931T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
AT02734556T 2001-05-23 2002-05-23 Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen ATE390931T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29340201P 2001-05-23 2001-05-23

Publications (1)

Publication Number Publication Date
ATE390931T1 true ATE390931T1 (de) 2008-04-15

Family

ID=23128937

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02734556T ATE390931T1 (de) 2001-05-23 2002-05-23 Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen

Country Status (17)

Country Link
US (2) US7304033B2 (de)
EP (1) EP1397153B1 (de)
JP (1) JP4837880B2 (de)
AT (1) ATE390931T1 (de)
AU (1) AU2002305716B2 (de)
CA (1) CA2447921C (de)
CY (1) CY1108127T1 (de)
CZ (1) CZ305380B6 (de)
DE (1) DE60225914T2 (de)
DK (1) DK1397153T3 (de)
ES (1) ES2302811T3 (de)
HU (1) HU229680B1 (de)
MX (1) MXPA03010568A (de)
NO (1) NO332465B1 (de)
PL (1) PL204899B1 (de)
PT (1) PT1397153E (de)
WO (1) WO2002094202A2 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) * 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
IL125928A (en) * 1996-03-20 2002-11-10 Bristol Myers Squibb Co The use of soluble ligands that react with CTLA4, B7, CD40, gp39 and / or CD28 for the preparation of pharmaceutical preparations
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
EP1294391B1 (de) * 2000-06-09 2012-08-15 Bristol-Myers Squibb Company Wirkstoffkombination zur verhinderung der transplantatabstossung
SI1935427T1 (en) * 2000-07-03 2018-05-31 Bristol-Myers Squibb Company USE OF HEATED CTLA4 MUTANT MOLECULES
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
AU2002243905B2 (en) * 2001-01-26 2007-11-08 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
PT1397153E (pt) * 2001-05-23 2008-06-12 Bristol Myers Squibb Co Métodos para proteger um transplante alogénico de ilhéus utilizando moléculas mutantes de ctla4 solúveis
US7541164B2 (en) * 2002-12-23 2009-06-02 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
ATE488600T1 (de) * 2002-12-23 2010-12-15 Bristol Myers Squibb Co Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
CA2534474C (en) * 2003-08-04 2014-09-23 Bristol-Myers Squibb Company Methods for treating cardiovascular disease using a soluble ctla4 molecule
US20070009517A1 (en) * 2003-08-25 2007-01-11 Mark De Boer Method of inducing immune tolerance
WO2006108035A1 (en) * 2005-04-06 2006-10-12 Bristol-Myers Squibb Company Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules
US8715649B2 (en) * 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
EP1909810B2 (de) * 2005-06-07 2017-08-23 The Regents of the University of Colorado Hemmer der serinprotease-aktivität und ihre verwendung in verfahren und zusammensetzungen zur behandlung von transplantat-abstossung und förderung des transplantat-überlebens
US9457070B2 (en) 2005-06-07 2016-10-04 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease
CA2909775A1 (en) * 2005-08-09 2007-03-29 Revivicor, Inc. Transgenic ungulates expressing ctla4-ig and uses thereof
WO2007047539A2 (en) * 2005-10-14 2007-04-26 Medtronic, Inc. Localized delivery to the lymphatic system
US10508144B2 (en) 2005-12-20 2019-12-17 Bristol-Myers Squibb Company Carbohydrate content of CTLA4 molecules
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
US7510844B2 (en) * 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
US20090029904A1 (en) * 2006-07-21 2009-01-29 Sean Oldham Compositions and methods for treatment of insulin-resistance diseases
WO2008014035A2 (en) * 2006-07-25 2008-01-31 The Regents Of The University Of California Modulation of nkg2d and method for treating or preventing solid organ allograft rejection
WO2008024242A2 (en) * 2006-08-18 2008-02-28 Argos Therapeutics, Inc. Use of cd83 in combination therapies
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
KR101383476B1 (ko) 2007-11-01 2014-04-11 아스테라스 세이야쿠 가부시키가이샤 면역억제 폴리펩티드 및 핵산
US20090191608A1 (en) * 2008-01-22 2009-07-30 Baylor Research Institute Pancreatic Islet Cell Preparation and Transplantation
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
AU2009293019A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care Inc. Solute concentration measurement device and related methods
EP2344540B1 (de) 2008-10-02 2017-11-29 Aptevo Research and Development LLC Multitarget-bindungsproteine mit cd86-antagonist
RU2506311C2 (ru) * 2008-10-30 2014-02-10 Йеда Рисёрч Энд Девелопмент Ко. Лтд. Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний
PT2365802T (pt) 2008-11-11 2017-11-14 Univ Texas Microcápsulas de rapamicina e utilização para o tratamento de cancro
WO2011014704A2 (en) 2009-07-30 2011-02-03 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
NZ810903A (en) * 2009-08-14 2024-08-30 Revivicor Inc Multi-transgenic pigs for diabetes treatment
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
CN106432474A (zh) 2010-03-12 2017-02-22 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
WO2011146395A2 (en) 2010-05-17 2011-11-24 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
EP2614083A2 (de) 2010-09-08 2013-07-17 Yeda Research and Development Co. Ltd Immunsuppresive wirkstoffkombination für stabiles und langfristiges anwachsen
EP2613801B1 (de) 2010-09-08 2016-06-08 Yeda Research and Development Co. Ltd. Zentrale anti-dritte-t-gedächtniszellen, und deren verwendung in einer 'anti-leukämie/lymphoma' behandlung
ES2680636T3 (es) 2011-02-14 2018-09-10 Revivicor Inc. Cerdos genéticamente modificados para xenotrasplante de xenoinjertos vascularizados y derivados de los mismos
EP2723370A4 (de) 2011-06-24 2015-06-03 Univ Colorado Regents Zusammensetzungen, verfahren und verwendung für alpha-1-antitrypsin-fusionsmoleküle
EP2753351B1 (de) 2011-09-08 2017-06-21 Yeda Research and Development Co. Ltd. Zentrale anti-dritte-t-gedächtniszellen, verfahren zur herstellung davon und verwendung davon in der transplantation und bei der krankheitsbehandlung
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
MX2015000237A (es) * 2012-06-27 2015-08-14 Orban Biotech Llc Proteinas de fusion ctla4 para el tratamiento de la diabetes.
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
BR112015024516A2 (pt) * 2013-03-28 2017-10-24 Bristol Myers Squibb Co métodos para identificar pacientes em risco de rejeição resistente ao bloqueio de coestimulação
WO2014182601A1 (en) * 2013-05-08 2014-11-13 Children's Medical Center Corporation A method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the atp/p2x7r axis)
EP3091991B1 (de) * 2013-12-13 2019-11-06 IsletOne AB Zusammensetzungen mit immunomodulatorischer wirkung
EP3089737B1 (de) 2013-12-31 2021-11-03 Rapamycin Holdings, LLC Orale rapamycinnanopartikelzubereitungen und verwendung
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
US11319359B2 (en) 2015-04-17 2022-05-03 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
US10933124B2 (en) 2015-07-16 2021-03-02 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
US11260027B2 (en) 2015-07-29 2022-03-01 Musc Foundation For Research Development Donor organ pre-treatment formulation
GB201611123D0 (en) 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
IT201800000534A1 (it) * 2018-01-03 2019-07-03 Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici.
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
EP3571295A1 (de) 2017-01-18 2019-11-27 Yeda Research and Development Co. Ltd Genetisch modifizierte vetozellen und verwendung davon in der immuntherapie
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
EP4219540A3 (de) 2017-10-10 2023-12-06 Alpine Immune Sciences, Inc. Ctla-4-variante immunmodulatorische proteine und verwendungen davon
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2022015872A (es) 2020-06-11 2023-05-16 Provention Bio Inc Metodos y composiciones para prevenir diabetes tipo 1.
CN115089718B (zh) * 2021-11-30 2024-05-28 杭州瑞普晨创科技有限公司 用于异种移植的免疫抑制剂组合和免疫抑制方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6685941B1 (en) * 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
IL92382A (en) * 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) * 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein
US7070776B1 (en) 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5770197A (en) * 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
DE122007000078I2 (de) 1991-06-27 2011-01-13 Bristol Myers Squibb Co CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5958403A (en) * 1992-02-28 1999-09-28 Beth Israel Hospital Association Methods and compounds for prevention of graft rejection
CA2133075A1 (en) 1992-04-07 1993-10-14 Craig B. Thompson CD28 Pathway Immunoregulation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5773253A (en) * 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
ES2240962T3 (es) 1993-06-04 2005-10-16 The United States Of America As Represented By The Secretary Of The Navy Metodo para estimular selectivamente la proliferacion de celulas t.
WO1994028912A1 (en) 1993-06-10 1994-12-22 The Regents Of The University Of Michigan Cd28 pathway immunosuppression
ATE188487T1 (de) 1993-09-02 2000-01-15 Dartmouth College Anti-gp39 antikoerper und deren verwendungen
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
JPH10504703A (ja) 1994-06-03 1998-05-12 アメリカ合衆国 Ｔ細胞の選択的刺激増殖方法
US6719972B1 (en) 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
AU2701895A (en) 1994-06-07 1996-01-05 Regents Of The University Of Minnesota Methods for inhibiting antigen specific t cell responses
AU4158396A (en) 1994-11-10 1996-06-06 Dana-Farber Cancer Institute Methods for inhibiting graft versus host disease in bone marrow transplantation
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
GB9506844D0 (en) * 1995-04-03 1995-05-24 Armitage Ian M Pharmaceutical microencapsulation
US5993800A (en) * 1995-06-05 1999-11-30 Bristol-Myers Squibb Company Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7041634B2 (en) * 1995-09-27 2006-05-09 Emory University Method of inhibiting immune system destruction of transplanted viable cells
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
IL125928A (en) * 1996-03-20 2002-11-10 Bristol Myers Squibb Co The use of soluble ligands that react with CTLA4, B7, CD40, gp39 and / or CD28 for the preparation of pharmaceutical preparations
KR19980066046A (ko) 1997-01-18 1998-10-15 정용훈 고역가의 CTLA4-Ig 융합단백질
ZA98533B (en) 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
WO1998056417A1 (en) 1997-06-11 1998-12-17 The United States Of America, Represented By The Secretary Of The U.S. Department Of The Navy Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses
WO1999039727A1 (en) 1998-02-04 1999-08-12 The General Hospital Corporation Costimulatory blockade and mixed chimerism in allotransplantation
IL126681A0 (en) 1998-10-21 1999-08-17 Opperbas Holding Bv Treatment of trauma-related conditions
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
WO2001090122A2 (en) 2000-05-23 2001-11-29 Genaissance Pharmaceuticals, Inc. Haplotypes of the ctla4 gene
CN101255192A (zh) 2000-05-26 2008-09-03 布里斯托尔-迈尔斯斯奎布公司 可溶性ctla4突变体分子及其应用
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
AU2006203199B2 (en) * 2000-05-26 2009-02-12 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
EP1294391B1 (de) * 2000-06-09 2012-08-15 Bristol-Myers Squibb Company Wirkstoffkombination zur verhinderung der transplantatabstossung
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
SI1935427T1 (en) * 2000-07-03 2018-05-31 Bristol-Myers Squibb Company USE OF HEATED CTLA4 MUTANT MOLECULES
AU2002243905B2 (en) * 2001-01-26 2007-11-08 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
US20030031652A1 (en) 2001-04-16 2003-02-13 Bernhard Hering Systems and methods for inducing mixed chimerism
PT1397153E (pt) * 2001-05-23 2008-06-12 Bristol Myers Squibb Co Métodos para proteger um transplante alogénico de ilhéus utilizando moléculas mutantes de ctla4 solúveis
US7541164B2 (en) 2002-12-23 2009-06-02 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
ATE488600T1 (de) 2002-12-23 2010-12-15 Bristol Myers Squibb Co Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
CA2534474C (en) 2003-08-04 2014-09-23 Bristol-Myers Squibb Company Methods for treating cardiovascular disease using a soluble ctla4 molecule

Also Published As

Publication number Publication date
EP1397153A4 (de) 2006-01-04
HUP0401590A3 (en) 2012-09-28
CZ305380B6 (cs) 2015-08-26
US20080160022A1 (en) 2008-07-03
EP1397153A2 (de) 2004-03-17
PL364578A1 (en) 2004-12-13
NO20035176L (no) 2004-01-05
CA2447921C (en) 2011-08-09
WO2002094202A2 (en) 2002-11-28
DE60225914T2 (de) 2009-07-23
JP2004535402A (ja) 2004-11-25
HUP0401590A2 (hu) 2004-11-29
WO2002094202B1 (en) 2003-07-31
CZ20033188A3 (cs) 2005-04-13
AU2002305716B8 (en) 2002-12-03
PT1397153E (pt) 2008-06-12
AU2002305716B2 (en) 2007-10-25
WO2002094202A3 (en) 2003-06-26
DE60225914D1 (de) 2008-05-15
US20030022836A1 (en) 2003-01-30
NO20035176D0 (no) 2003-11-21
NO332465B1 (no) 2012-09-24
US7829534B2 (en) 2010-11-09
CY1108127T1 (el) 2014-02-12
HU229680B1 (hu) 2014-04-28
DK1397153T3 (da) 2008-05-26
PL204899B1 (pl) 2010-02-26
US7304033B2 (en) 2007-12-04
MXPA03010568A (es) 2005-03-07
EP1397153B1 (de) 2008-04-02
CA2447921A1 (en) 2002-11-28
ES2302811T3 (es) 2008-08-01
JP4837880B2 (ja) 2011-12-14

Similar Documents

Publication Publication Date Title
ATE390931T1 (de) Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
EA200870380A1 (ru) Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-vi для лечения или предупреждения диабета
DE69716449D1 (de) Substituierte zyklische amine als metalloproteaseinhibitoren
NO20061194L (no) Mitotiske kinesininbibitorer
MY118222A (en) Heterocyclic compounds as inhibitors of rotamase enzymes
TW200716531A (en) Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
AP2003002824A0 (en) Gyrase inhibitors and uses thereof
DE60309701D1 (de) 2-ureido-6-heteroaryl-3h-benzoimidazol-4-carbonsäurederivate und verwandte verbindungen als gyrase und/oder topoisomerase iv inhibitoren zur behandlung von bakteriellen infektionen
TW200603728A (en) A method for treating plants or plant parts
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
BRPI0509186A (pt) 1,3-diaminopropanos 2-amino-e 2-tio-substituìdos
CY1109245T1 (el) Ενωσεις χρησιμες στην θεραπεια ανθρακα και στην αναστολη θανατηφορου παραγοντα
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
BR0213138A (pt) Métodos de tratar ou prevenir mal de alzheimer e uma doença distinguida por depósito de beta-amilóide no cérebro, de tratar um paciente que tenha, ou de prevenir um paciente de contrair uma doença ou condição, de produzir um complexo de beta-secretase e de inibir a produção de placa beta-amilóide em um animal, composição e uso de um composto
EA200200307A1 (ru) Радиоактивные фармацевтические продукты и способ их получения
SG10201810449XA (en) Organoarsenic compounds and methods for the treatment of cancer
BR9508342A (pt) Compostos orgânicos
DE69822626T8 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
DE59109225D1 (de) Verwendung von pyridylmethylsulfinyl-1h-benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
BR0313000A (pt) Compostos, composição farmacêutica e método para efetuar a inibição da enzima pde4, realçar a cognição e/ou tratar a psicose em um paciente
HUP0103660A2 (hu) Mikróbaeredetű hialuronsavbontó enzimet tartalmazó gyógyászati készítmény
BR0316245A (pt) Atividade antimicrobiana de espécie de oxigênio reativo produtora de anticorpos
DE69803264D1 (de) 1,3-diphenylpropanderivate mit hemmender aktivität gegen tyrosinase und verfahren zu deren herstellung
DE69838002D1 (de) Substituierte 11-phenyl-dibenzazepin-verbindungen, die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1397153

Country of ref document: EP